Kerajaan bersetuju tidak meneruskan perkhidmatan konsesi perolehan ubat dan peralatan perubatan dari Pharmaniaga yang akan berakhir pada 30 November ini.
Pharmaniaga owned by Bstead ..both shares dropped significantly because the previous Pakatan (lucky the gov went to Holland ) and both Bstead (owner of) Pharmaniaga will regain concession for supplying medical and pharmaceuticals to Government hospitals.. so RM billion incoming revenue.. plus Covid 19 vaccine this also will add more billion to Pharmaniaga and will reflect to Bstead..
So thos3 who are inside.. hold.. Vaccine just around the corner few more months to come..if every student must be vaccinated about 6m student x RM200-300 per pax..RM1.8B..
KYY is just typical speculator..he put nasty article on pharma is to let the people not to dump glove share..glove & vaccine is contradict to each other ..when vaccine is ready mean not more attention to glove share..simple..remember Hengyuan, Jaks, Dayang guys..vaccine will be in play eventually..
I am so thrilled with strong conviction by traders and investors alike that vaccine will eventually ready for the masses in foreseeable timeline. Again this conviction is not entirely baseless at all. With govt announcement for vaccine's 'fill and finish' by two govt-linked pharmas should not be taken lightly. I am sure they've really thought out the consequences before making public announcement like this. If thing went sour or extended to unknown future, it won't affect much to general public perception since we NOT are actually the one who producing vaccine but merely bottling and packaging. Backlash from business community, traders and investors who betting on it is though, highly expected. As much we all hope vaccine will eventually emerged, producing viable vaccine is not a short term affair. With my limited knowledge and readings, I have to say I can't anticipate what's really brewing under the scene unless you've got insider tips to hold on to.
Athila noted that it was not a surprise to her that Pharmaniaga and Duopharma have been tasked with the COVID-19 packaging process in Malaysia, given that both have the largest manufacturing and pharmaceutical facilities in Malaysia as well as a reliable nationwide logistic network already in place.
She added that more than 50% of Pharmaniaga and Duopharma's products are supplied to the Ministry of Health's hospitals and facilities.
The vaccine story aside, Equitiestracker Holdings Bhd head of research Lim Tze Cheng said the demand for vitamins and general supplements has been strong during the movement control order (MCO), which would see pharmaceutical companies that deal more on supplements seeing stronger numbers in upcoming quarters.
Covid-19 Vaccine Latest Updates: Oxford’s Covishield in India by ‘end of year’; Pfizer shot shows promise
Coronavirus (Covid-19) Vaccine Latest Update: While the promising results showed by experimental Covid-19 vaccines being developed by University of Oxford and Moderna Inc in early human testing have grabbed the spotlight in the past week, raising hopes of early availability in the market, a World Health Organization (WHO) expert said their first use cannot be expected until early 2021.
“Several vaccines are now in Phase 3 trials and none have failed, so far, in terms of safety or ability to generate an immune response. Realistically, it is going to be the first part of next year before we start seeing people getting vaccinated,” Reuters quoted said Mike Ryan, head of WHO’s emergencies programme, as saying.
Meanwhile, latest results from Oxford university and Moderna show that two doses of a vaccine may be better than one in getting protection from the novel coronavirus.
Presently, there are more than 150 vaccine candidates that are in various stages of trials against the coronavirus, according to the World Health Organisation. Out of them, about two dozen are undergoing human clinical trials.
Oxford-AstraZeneca coronavirus vaccine status
Results published this week of early human trials of the AZD1222 vaccine, based on a chimpanzee adenovirus called ChAdOx1, developed by the University of Oxford and drugmaker AstraZeneca showed that it produced a dual immune response in people aged between 18 and 55 years.
The vaccine increased levels of both protective neutralising antibodies and immune T-cells that target the virus, according to the study organisers. “Our hope is that we can actually start delivering a vaccine before the end of the year,” Bloomberg quoted AstraZeneca Chief Executive Officer Pascal Soriot as saying.
A single dose of the vaccine elicited an increase in antibodies specifically against the spike protein by the first 28 days.
The Oxford shot is already undergoing a combined Phase II/III trials in the UK, Brazil and South Africa. The Serum Institute of India hopes to embark on phase III human clinical trials with the vaccine candidate by August and it may be launched as early as November.
Adar Poonawalla, CEO of Serum Institute of India, said the cost of the vaccine is estimated to be below Rs 1,000 and will be called Covishield in India.
(CNN)Much of the world has pinned its hopes on a vaccine as a way out of the Covid-19 pandemic that has infected more than 15 million and killed more than 630,000 people globally.
The World Health Organization says there are 25 potential coronavirus vaccines in clinical trials internationally.
Here in the United States, the government has put its money behind several different vaccine candidates through Operation Warp Speed.
One of those vaccines is being developed by the Vaccine Research Center at the National Institutes of Health's National Institute of Allergy and Infectious Diseases, in partnership with the biotechnology company Moderna. The vaccine is expected to enter Phase 3 testing next week. This phase of the trial is expected to involve 30,000 volunteers and will test whether the vaccine protects people against the coronavirus.
The vaccine uses messenger RNA (mRNA), which are cells used to build proteins -- in this case, the proteins that are needed to build the coronavirus' spike protein, which the virus uses to attach itself to and infect human cells. Once the immune system learns to recognize this target -- thanks to the vaccine -- it can mount a response faster than if it encountered the virus for the first time due to an infection.
Early results from the Phase 1 study were published in the New England Journal of Medicine in mid-July. The study showed that the vaccine, given at three different doses, triggered an immune response in the people who received it (the higher the dose, the higher the immune response). More than half of the participants experienced side effects including fatigue, chills, headache, muscle pain and pain at the injection site. The Phase 3 trial will involve the middle dose --100 micrograms (µg).
Dr. Barney Graham is the deputy director of the Vaccine Research Center. He spoke to Dr. Sanjay Gupta to explain a little bit about the technology behind the Moderna vaccine. What follows is a portion of their conversation, edited for length and clarity, to explain what is happening inside the body.
A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. Their Phase I/II trial, reported on July 20 in the journal Lancet, found that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses. The vaccine is now in a Phase II/III trial in England, as well as Phase III trials in Brazil and South Africa. The project may deliver emergency vaccines by October. AstraZeneca has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses.
The German company BioNTech has entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop their mRNA vaccine. In July, they posted preliminary results from their Phase I/II trials in the United States and Germany. They found that the volunteers produced antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. Some volunteers experienced moderate side effects such as sleep disturbances and sore arms.
The company expects to start Phase III trials by the end of July. On July 22, the Trump administration awarded a $1.9 billion contract for 100 million doses to be delivered by December and the option to acquire 500 million more doses. If approved, Pfizer said they expect to manufacture over 1.3 billion doses of their vaccine by the end of 2021.
Keyman188 foresee a lot of traders & investors will surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-
1) Pharma - TP 10.00
2) Dpharma - TP 7.50
Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-
1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available
2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.
3) If we have the capacity, we will also offer our fill and finish service to other countries.
@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........
Listen to the above and do a thorough research to assess if it is worth investing in the OTC biotech company Cytodyn which is about to obtain FDA's approval on its amazing drug Leronlimab which can the solution to the global Covid-19 pandemic.
"As the Covid-19 outbreak is resulting in an influx of treatment activities at government medical facilities, we expect Pharmaniaga's L&D activities, and consequently sales, to pick up in 2QFY20F, which represents the peak period of domestic Covid-19 infections," this upcoming result on 23 aug is 2Q2020...yehaa.. last quarter profit 22.4mil..saya target profit 2Q 30mil..upside profit by 33%..mesti ramai yg nk ride
cgs-cimb new TP is rm3.40..this without factor in vaccine bottling revenue... after superb result in 2Q..most analyst will revise upside target price..mark my words..
We make no changes to our earnings estimates as we have not factored in the potential contribution from the fill-and-finish works for the Covid-19 vaccine, pending further details.
cgs-cimb new TP is rm3.40..the current price is stabilised already if it is not rising up next monday..this company market cap is huge..small traders not able to play around with it..but the last 2 days seem profit taking activities took place..lets see the direction next mon..hopefully will rebound slightly..and further up the day onwards..
I am not convinced that vaccine can be ready as early by end of this yr. While there is so many positive and hopeful news, human can easily trapped on confirmation bias. They seek news that confirms to their believe and most times, refuse to accept contradictive ones. I am included. If you read the announcement by KJ recently, there is no confidence on vaccine. It is just about we are getting ready when vaccine is available.
u r true indeed..but the target price is without vaccine bottling revenue..its 2quarter will be improve due to higher demand in medicine during covid..
its not about selling vaccine..its about bottling charges that generate revenue..u misunderstood brader..although vaccine is free also can generate income to pharma..
Glove is definitely needed. With vaccine around, the ASP will be under control. Once ASP is under control, the glove earning and return is no more ridiculous number, like PE 30, 40 or 60. Soon the gambling mode will switch back to investment mode for glove counter. About vaccine, to have 100% effective vaccine for covid 19 may take longer time, but who say we must wait for the 100% working vaccine? Phase 3 is to look for the right dosing for each individual if not wrong. How about inject a safe dosage for everyone for the phase 1? Maybe follow by Phase 2 injection as a booster and Phase 3 and so on, like hep B. In this case, those pharma company will earn multiple time instead of just 1 time.
@Just2Earn, agreed, just wait now since moderna is entering its trial 3 phase this month july so lets hope for some good news.
sad thing is my gf is in overseas, we were planning for serious commitments now i dont know when i can visit her..every single day im hoping for a hope and vaccine news...sigh...
Gloves will be less attractive when Covid 19 vaccines will arrive.. that why people in gloves counter feeling some sort of uncertainty if glove can maintain their high price.. for sure when vaccines come.. gloves price will be normal like before covid 19 be'ause people are not too much worried and we can live normal again.. there is still demand for glove but at a normal level and normal price.. or may be up to 2021 when all the countries have enough gloves stocks then they will stop order in a big way. They will use their gloves untill finish.. may be in 2023 they will re order our gloves..
Coronavirus vaccine may be available in Singapore only at the end of next year: MOH A research officer checks the quality of cells and virus that are used in the development of a vaccine. A research officer checks the quality of cells and virus that are used in the development of a vaccine.ST PHOTO: KELVIN CHNG PUBLISHEDJUL 24, 2020, 7:00 PM SGT FACEBOOKTWITTER Rei Kurohi SINGAPORE - A Covid-19 vaccine may become available in sufficient doses only towards the end of next year, the Health Ministry director of medical services Kenneth Mak said.
He said Singapore is proactively working with vaccine developers, pharmaceutical companies and research institutions on research efforts into a Covid-19 vaccine.
Discussions have also begun to ensure Singapore will have access to vaccines when they become available, he told a virtual press conference on Friday (July 24).
But even though a number of companies have announced that they have started on phase three trials, which are a "relatively later stage" of the process of vaccine development, Associate Professor Mak said there may yet be failures in delivering a vaccine that is safe and effective.
"Practically speaking, we expect, realistically, a vaccine to be available perhaps next year rather than this year," he said.
"Given the global demand for these vaccines, it may not even be in the beginning of next year but perhaps towards the end of next year, when we might see vaccines produced in sufficient doses, and available then for procurement and to be delivered into Singapore."
He added that at this stage, it is still not known which of the vaccine candidates undergoing trials will ultimately be the one that is most likely to be brought into Singapore
But even though a number of companies have announced that they have started on phase three trials, which are a "relatively later stage" of the process of vaccine development, Associate Professor Mak said there may yet be failures in delivering a vaccine that is safe and effective.
"Practically speaking, we expect, realistically, a vaccine to be available perhaps next year rather than this year," he said.
"Given the global demand for these vaccines, it may not even be in the beginning of next year but perhaps towards the end of next year, when we might see vaccines produced in sufficient doses, and available then for procurement and to be delivered into Singapore."
He added that at this stage, it is still not known which of the vaccine candidates undergoing trials will ultimately be the one that is most likely to be brought into Singapore
Seems Gloves people in worried... No need to worry.. just hold your gloves tightly.. later will get bonus 1:2 or 1:1.. then we will buy the later at cheaper price.. may be RM3.5 per share after bonus issue..
At PE ratio 30x, this stock should be priced at around Rm1.02 which is 3x lower than current price. This is the initial price of vaccine's bottling and packaging hope.
China sinopharm coming very soon . The whole world top scientists are working on the vaccine. Then pharma stocks price will be up n up. Make huge profit then.
Goldberg Dr Fauci believes vaccine will only be available well into 2021. ------------------------------------------------------- Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he believes that hope is warranted and that a vaccine could stop the pandemic in its tracks, but he also doesn't believe that will happen until well into 2021.
The first Phase 3 coronavirus vaccine trial in the US is expected to begin next week. "I think as we get into 2021, several months in, that you would have (a) vaccine that would be widely available to people in the United States," Fauci told the Washington Post's Bob Costa during a Post Live event.
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 739 views | 3 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 691 views | 7 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Jingann
2 posts
Posted by Jingann > 2020-07-24 19:38 | Report Abuse
No more vaccine bottling ? Still can limit up ?